S2.1 Enzyme replacement therapy (ERT)
in Glycogen Storage Disease Type II:
the first treatment developed by Angelini, Corrado et al.
204
Proceedings of the Meeting Course on Type II Glycogenosis: a network for the treatment of Pompe disease
SESSION 2. MANAGEMENT OF POMPE DISEASE
S2.1 Enzyme replacement therapy (ERT)  
in Glycogen Storage Disease Type II:  
the first treatment developed
Corrado Angelini, Claudio Semplicini, Marina Fanin, 
Annachiara Nascimbeni, Enrico Peterle, Elena Pegoraro
Department of Neurosciences, University of Padova, Padova, Italy
E-mail: corrado.angelini@unipd.it
Since 2006 ERT is available in Europe and numerous stud-
ies were reported both in infantile and in juvenile - adult patients 
that demonstrated variable efficacy (1, 2). We have followed in-
fants treated with ERT either early in the first year or later. In 
one child with onset at birth, diagnosed in the third day of life 
we observed an excellent long-term clinical response on severe 
bradycardia and reduction of left ventricular mass index in car-
diomyopathy (3) while in another child where the therapy was 
post-pond no such response was observed: in this second case 
a large connective tissue replacement was present in the biopsy 
after ERT. In juvenile and late onset cases a large experience 
was collected by the Italian group of GSDII (4) and will be soon 
reported in full. Beside the clinical follow-up we also did a re-
peated second biopsy after ERT in two cases after 6 months in 
a 17 year old juvenile case and after 36 months of ERT in a 63 
year ventilator dependent woman and we observed less degree 
of vacuolization in muscle fibers. We documented that ERT im-
proves muscle fiber trophism and decreases PAS positivity, as 
well as the extensive muscle autophagic vacuolization. We did 
observe that ERT is effective in both infantile and late-onset GS-
DII cases, but at a different extent. To explain the difference of 
ERT in late onset cases we suppose that fiber sarcolemmal mem-
brane  compartimentalization  around  autophagosomes  might 
contribute to the different response in infants and adults; in fact 
we previously reported (5) that there is a greater degree of fiber 
sarcolemmal membranes around vacuoles in muscle fibers of 
late-onset GSDII, versus classical infantile Pompe patients. This 
protective mechanism may influence the delivery of ERT in adult 
cases. Furthermore a high antibody titer against recombinant en-
zyme has been observed (1, 6) both in infants and in adults and 
might influence ERT efficacy. Finally body composition (I.e fat 
and connective tissue) and the different mannose receptor den-
sity in various tissues (heart, skeletal muscle, diaphragm) has to 
be considered. ERT is the first treatment developed for GSDII, 
but it needs further refinements. Several trials are in fact explor-
ing new avenues of treatment (chaperons, new compounds with 
different affinity for mannose receptor, immunotherapy, etc.). 
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ated with one of the following criteria: PaCO2 > 45 mmHg; 
episodes of desaturation during a night-time monitoring (SaO2 
<88% for 5 consecutive minutes); MIP < 60 cm H2O or a FVC 
< 50% of predicted values in patients with progressive neu-
romuscular diseases. According to the international consensus 
additional physiological criteria are: PaO2 in the waking state 
and during clinical stability < 60 mmHg, vital capacity (VC) 
< 20-30% predicted or < 1.0 L, maximum pressure inspiratory 
(MIP) < 30 cm H2O, unlike the CV in the transition from up-
right to supine position > 25%; tachypnoea: respiratory rate > 
27 breaths / min. Noninvasive mechanical ventilation helps pa-
tients to breathe when the muscle becomes deficient. It inter-
acts with the patient having an adequate alveolar ventilation, 
improving  oxygenation  and  reducing  hypercapnia.  Patients 
treated with noninvasive mechanical ventilation have reduced 
dyspnea and hypersomnia and improved sleep; also fatigue 
disappeared in most patients. 
In patients with Pompe disease progressive muscle weak-
ness renders ineffective the mechanism of cough, with stagnation 
of secretions. This causes atelectasias, pneumonia, acute respira-
tory failure with need for frequent hospitalization. airway clear-
ance techniques can facilitate the mobilization and removal of 
secretions that clutter the airways. The use of airway clearance 
techniques, including assisted coughing techniques, both manual 
and mechanical, and secretion mobilization techniques, is strong-
ly recommended. These techniques should always be included in 
the treatment of chronic NMD patients. Chest percussion and vi-
bration can help to mobilize peripheral airway secretions but they 
are not substitutes for coughing and, unlike for assisted coughing, 
have never been shown to decrease pulmonary morbidity and mor-
tality. Cough can be assisted by manual and mechanical means. 
There are a wide variety of techniques available from which to 
choose, ranging from manual techniques to mechanically assisted 
maneuvers. The possibility of using devices for assisted coughing 
should be individually evaluated. 
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patients identified by the neonatal screening and treated earlier 
than historical patients showed improved outcome in terms of 
motor activity and ventilatory-free survival.
The immune status of PD patients has emerged as another 
important factor that impacts ERT efficacy. In a recent study 
the effects of ERT in 11 cross-reactive immunological material 
(CRIM) negative patients were compared with those obtained in 
21 CRIM positive patients (7). CRIM-positive patients showed 
lower antibody titers, and a better response to ERT, while CRIM-
negative patients showed an attenuated response to enzyme with 
significantly decreased survival, invasive ventilation-free sur-
vival, less improvement in cardiac response, and regression of 
motor milestones.
Other studies implicated cellular abnormalities triggered 
by glycogen storage as additional factors affecting ERT effica-
cy. Cardone et al. (8) demonstrated an abnormal recycling of the 
cation-independent  mannose-6-phosphate  receptor  (CI-MPR) 
in cultured PD fibroblasts. As the integrity of the CI-MPR path-
way is essential for efficient uptake and lysosomal delivery of 
recombinant enzymes used for ERT, the abnormal trafficking of 
the receptor in PD fibroblasts resulted in an impaired correction 
of enzyme activity by rhGAA. The abnormalities of CI-MPR 
trafficking were more prominent in fibroblasts from severe and 
intermediate PD patients, apparently correlating with disease 
severity. 
Raben  et  al.  (9)  demonstrated  that  abnormalities  of  au-
tophagy also impact on ERT efficacy and that suppression of 
autophagy in combination with ERT resulted in a near-complete 
glycogen clearance and restoration of skeletal muscle architec-
ture in a mouse model of PD.
The limitations of ERT efficacy point to the need for im-
proved therapeutic strategies such as immune modulation, early 
start of ERT, pharmacological chaperone therapy (10) and its 
combination  with  ERT  (11),  substrate  reduction  (12).  Gene 
therapy is currently under investigation as an alternative thera-
peutic option for the treatment of PD patients.
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Until the end of the last century the management of Pompe 
disease  (PD)  was  exclusively  based  on  multidisciplinary  in-
terventions aimed at providing support therapies to patients. 
Enzyme replacement therapy (ERT) with recombinant human 
GAA (rhGAA, Myozyme) was introduced in 2000 and is pres-
ently the only approved pharmacological treatment for PD. rh-
GAA is administered periodically to patients by an intravenous 
route, and is internalized by cells and target tissues through the 
mannose-6-phosphate receptor pathway.
The  first  clinical  study  on  ERT  in  PD  was  conducted 
in four Dutch patients affected by the infantile form of the 
disease (1) that were treated for 36 weeks with an enzyme 
preparation derived from transgenic rabbit milk. Both the re-
sults of this trial and those of a long-term follow-up study (2) 
supported the efficacy of ERT on cardiac involvement, motor 
activity, and patients’ survival. Since then a number of reports 
of almost a hundred patients treated with rhGAA, mostly with 
the classical infantile-onset PD, were published in the litera-
ture. Recently formal studies on the efficacy of ERT in PD 
were performed also in patients with the juvenile/adult forms 
of the disease (3, 4). An international PD registry has become 
active since 2004, and will likely add further information on 
long-term efficacy of ERT.
Like  for  other  lysosomal  storage  diseases  ERT  in  PD 
showed  important  success  together  with  some  limitations. 
Specifically, excellent results were obtained in terms of func-
tional correction of cardiac disease and of glycogen clearance 
in liver. On the other hand it became evident that correction of 
skeletal muscle pathology is a difficult challenge and that not 
all patients respond equally to ERT (5). Several factors appear 
to affect the efficacy of ERT and the outcome of PD patients, 
including age at the start of treatment, stage of skeletal muscle 
damage, antibody responses, insufficient targeting of rhGAA 
to skeletal muscle and high clearance of the enzyme by the 
liver.
It was a common experience of physicians involved in the 
care of PD patients that the earlier was start of treatment, the 
better would be the outcome. This concept was formally proven 
by recent studies done in Taiwan, where a large-scale newborn 
screening  pilot  program  was  performed  during  the  past  few 
years (6). The results from this study clearly indicated that in 